Cargando…
Trypanosoma cruzi 80 kDa prolyl oligopeptidase (Tc80) as a novel immunogen for Chagas disease vaccine
BACKGROUND: Chagas disease, also known as American Trypanosomiasis, is a chronic parasitic disease caused by the flagellated protozoan Trypanosoma cruzi that affects about 8 million people around the world where more than 25 million are at risk of contracting the infection. Despite of being endemic...
Autores principales: | Bivona, Augusto E., Sánchez Alberti, Andrés, Matos, Marina N., Cerny, Natacha, Cardoso, Alejandro C., Morales, Celina, González, Germán, Cazorla, Silvia I., Malchiodi, Emilio L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5895069/ https://www.ncbi.nlm.nih.gov/pubmed/29601585 http://dx.doi.org/10.1371/journal.pntd.0006384 |
Ejemplares similares
-
Cruzipain and Its Physiological Inhibitor, Chagasin, as a DNA-Based Therapeutic Vaccine Against Trypanosoma cruzi
por: Cerny, Natacha, et al.
Publicado: (2020) -
Activity of Estafietin and Analogues on Trypanosoma cruzi and Leishmania braziliensis
por: Sülsen, Valeria P., et al.
Publicado: (2019) -
Engineered trivalent immunogen adjuvanted with a STING agonist confers protection against Trypanosoma cruzi infection
por: Sanchez Alberti, Andrés, et al.
Publicado: (2017) -
Mucosal Heterologous Prime/Boost Vaccination Induces Polyfunctional Systemic Immunity, Improving Protection Against Trypanosoma cruzi
por: Sanchez Alberti, Andrés, et al.
Publicado: (2020) -
In Vitro, In Vivo, and In Silico Studies of Cumanin Diacetate as
a Potential Drug against Trypanosoma cruzi Infection
por: Sánchez Alberti, Andrés, et al.
Publicado: (2021)